During the past decade, CHU de Grenoble; Neurologie conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "CHU de Grenoble; Neurologie" are "Multiple Sclerosis" (2 trials) and "Multiple Sclerosis, Relapsing-Remitting" (1 trials). Many other conditions were trialed in "CHU de Grenoble; Neurologie" in a lesser frequency.

Most popular intervention types in "CHU de Grenoble; Neurologie" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Ocrelizumab" (2 trials), "Ocrelizumab 300 mg" (1 trials) and "Ocrelizumab 600 mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "CHU de Grenoble; Neurologie" are 3 trials for "All" genders.

Currently, there are NaN active trials in "CHU de Grenoble; Neurologie". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in CHU de Grenoble; Neurologie, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in CHU de Grenoble; Neurologie, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".